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Perasafe, Virkon and bleach are bactericidal for
Burkholderia pseudomallei, a select agent and the
cause of melioidosis
Madam,
Our diagnostic and research microbiology laboratories are
within Sappasithiprasong Hospital, a 1000-bedded district
hospital in northeast Thailand. Every year we process hundreds
of clinical samples that contain Burkholderia pseudomallei. This
category B select agent is a Gram-negative, non-spore-forming
bacillus and the cause of melioidosis.1,2 Furthermore, up to 80%
of soil samples in northeast Thailand contain B. pseudomallei at
counts that can reach >10 000 colony-forming units (cfu)/g of
soil.3–5 Hospital ﬂoors become contaminated with soil particles
deposited from footwear, and some connecting corridors on the
ground ﬂoor of the hospital are intermittently ﬂooded during
the rainy season. Our hospital uses reusable endotracheal and
nasogastric tubes, and these will often become contaminated
with B. pseudomallei, since 50% of patients with melioidosis
develop pneumonia, the median B. pseudomallei count in respir-
atory secretions has been reported to be 1.1105 cfu/mL, and seri-
ously ill patients with melioidosis rarely die in the absence of an
endotracheal tube.6
We are evaluating the bactericidal efﬁcacy of chemical germi-
cides used to decontaminate our microbiology laboratories and
reusable medical equipment. Here, we report the results of a pilot
study on the efﬁcacy of Perasafe (Antec International Ltd, UK),
Virkon (Antec International Ltd) and bleach against B. pseudomal-
lei. Perasafe, a commercial peracetic acid disinfectant, is used to
decontaminate reusable endotracheal and nasogastic tubes. A Per-
asafe solution is made each week and aliquots used multiple times
over a period of ﬁve days. Used tubes are taken to a central area for
cleaning to remove organic material followed by immersion for
30 min in 0.2% Perasafe and then rinsing using prechlorinated tap
water. A 1% (w/v) solution of Virkon is used in the microbiology
laboratory for environmental cleaning and for initial decontamina-
tion of disposables such as swabs prior to incineration. Bleach is
inexpensive, and may be used during clean up of spills involving
cultured material.
Solutions of 0.2% Perasafe, 1% Virkon and 0.5% sodium hypochlo-
rite (bleach) (Bornnet Corporation Company Ltd, Bangkok,
Thailand) were prepared as recommended by the manufacturer.
In addition, aliquots of Perasafe being used by the hospital to
decontaminate reusable equipment were collected at the end of
days 1, 3 and 5. Bactericidal activity was evaluated for 10 clinical
isolates of B. pseudomallei cultured from patients presenting toour hospital. The efﬁcacy of the three chemical germicides was
tested using a suspension assay with a contact time of 30 min. A
bacterial suspension was prepared as follows. Six colonies picked
from Columbia agar (Oxoid, Basingstoke, UK) were resuspended
in 10 mL of tryptone soya broth (TSB, Oxoid) and incubated over-
night at 37 C in air with shaking at 150 rpm. Each broth was
then diluted 1:10 in fresh TSB and incubated as before for 4 h to
achieve a turbidity of 2.0–2.1 MacFarland (w2109 cfu/mL). Each
bacterial suspension was diluted to 1:10 by adding 130 mL of
suspension to 1170 mL of 0.2% Perasafe, 1% Virkon, 0.5% sodium
hypochlorite or distilled water; each was prepared in duplicate
for all isolates. Tubes were maintained at room temperature
(25 C) for 30 min and then centrifuged at 10,000 rpm for 2 min.
Pellets were washed three times with sterile distilled water prior
to resuspension to a volume of 1300 mL. The viable colony count
was performed on Columbia agar. A 100 mL volume of neat solution
from each tube was spread plated in triplicate on to Columbia agar
and the remaining solution transferred into 9 mL TSB which was
incubated at 37 C in air for 48 h before subculture in triplicate
on to Columbia agar. All agar plates were incubated at 37 C in
air, inspected daily, and a colony count performed on day 4. The
initial bacterial inoculum was deﬁned using colony counts as
a median of 2.2108 cfu/mL (range: 1.4108–3.7108).
The three germicides were 100% bactericidal for all 10
isolates under these conditions, with no growth observed on
any of the agar plates on day 4. This included all Perasafe
samples that were in use by the hospital for cleaning of reusable
equipment. There was no reduction in inoculum for the control
growth tube. We conclude that the use of Perasafe to clean
reusable endotracheal and nasogastric tubes appears to be
effective, and that 1% Virkon with a contact time of 30 min
will be cidal for B. pseudomallei. We stress that cleaning of re-
usable equipment is critical, together with the disposal of tubes
that have physical signs of wear. This is an important ﬁnding for
melioidosis-endemic, resource-restricted settings where reus-
able equipment is commonplace. We are not yet reassured
that bleach is effective for environmental cleaning since the
contact times used in this pilot study would not be achieved
during routine surface cleaning, and studies are ongoing using
shorter contact times.
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Investigation of possible routes of transmission of
group B streptococci to humans outside the
neonatal period
Madam,
Little is known about how adult humans acquire group B strep-
tococcus (GBS). The organism is a commensal and causesmastitis in
cattle, and therefore cattle may be a reservoir for human GBS.
Human GBS strains may have arisen from a bovine ancestor, and
aminority of bovine and human GBS isolates are indistinguishable.1
Although direct exposure to cattle has been reported to be associ-
ated with human GBS colonisation, it is implausible that this could
account for the entire burden of human GBS colonisation.2
Streptococci are thermoduric and acidophilic, and therefore GBS
in cows’ milk might survive pasteurisation and stomach acid to
establish human colonic carriage. A PubMed search identiﬁed no
reports speciﬁcally addressing the effectiveness of pasteurisation
at killing GBS. We therefore investigated the ability of GBS to
survive in milk under domestic-type conditions and to survive pas-
teurisation temperatures, and the presence of GBS in shop-bought
milk and milk products.
To ascertainwhether GBS can survive or multiply in cows’milk we
inoculatedninemilk sampleswith102–103 cfu/mLofaclinical isolateof
GBS. Three samples eachwere held overnight at 4 C, at room temper-
ature and at 37 C, and then subcultured on to blood agar. Milk at 4 C
yielded GBS at a density equivalent to the original inoculum, whereas
Open access under CC BY license.the samples held at higher temperatureswere overgrownwith Bacillus
spp., and in these samples GBS could not be identiﬁed.
We next purchased four milk, ﬁve cream, six yoghurt and
seven cheese samples from different retailers. Aliquots of 100 mL
and 1 mL were cultured on blood agar and in cooked meat broth,
respectively. GBS were not isolated from any of these samples. To
improve the sensitivity of GBS detection, 32 aliquots of 5 mL, from
eight milk sources, were centrifuged at 3000 r.p.m. for 3 min,
a 1 mL deposit re-centrifuged at 4000 r.p.m. for 1 min, and
100 mL of this deposit was cultured on blood agar. No GBS were
isolated.
To investigate the heat tolerance of GBS we heated 1 mL
volumes of 1–3108 cfu/mL broth suspension to 40, 50, 60, 72,
75, 80 and 83 C for 20 s, before cooling on ice to <10 C; repeated
in triplicate.3 The times taken to reach the target temperatures
were w2, 3, 4, 6, 6, 10 and 19 min respectively, so that samples
heated to the highest temperatures were exposed for longer. GBS
survived at all temperatures, except 83 C. However, temperatures
of 40–60 C reduced bacterial counts 106-fold, and temperatures of
72–75 C 107–108-fold. The maximum legal limit for somatic bacte-
rial counts in rawmilk is 4105 cfu/mL.4 When 2–3.7105 cfu/mL
were heated to 72 C, no GBS survived. Finally, four different clinical
isolates of GBS (105–106 cfu/mL) were heated to 72 C. No GBS
survived.
Our data indicate that although GBS are to some extent thermo-
duric, the log kill at pasteurisation temperatures comfortably
exceeds the maximum permissible microbial contamination of
raw milk. Unsurprisingly we were unable to culture GBS from 22
shop-bought milk or milk products: these products are therefore
unlikely to be a source of transmission of GBS to humans.
Others have postulated environmental contamination as a route
of human-to-human transmission of GBS.5We investigated survival
of GBS on environmental surfaces by artiﬁcially contaminating
deﬁned areas of 6 cm2 onwood, glass, fabric, plastic andmetal using
swabs soaked in suspensions of GBS containing 103–106 cfu/mL. The
contaminated materials were left overnight at room temperature,
after which the entire inoculated areas were sampled using moist-
ened swabs. Viable GBSwere isolated fromall surfaces exceptmetal.
We then sampled more than 20 surfaces (toilet light pulls and
switches, door handles, sink taps, alcohol and soap dispensers, diag-
nostic ultrasound machine switches and probe, drawer handles,
examination light handle, baby scales and delivery bed stirrups) in
the delivery suite of a tertiary obstetric hospital. This setting was
chosen as an area of the hospital where there might be a high risk
of environmental contamination with GBS. We isolated coagulase-
negative staphylococci and Bacillus spp., but no GBS. Thus, although
GBS can survive on surfaces (at least when the inoculum is high), in
practice we did not ﬁnd environmental contamination with GBS in
a high risk clinical area.
We conclude that GBS is unlikely to be transmitted from cows to
man in pasteurised milk, and neither is it likely to be passed from
human-to-human on fomites. The environmental reservoir for
human GBS carriage/disease is unknown, although some have sug-
gested other foods including ﬁsh and faecal contamination of veg-
etables. Alternatively, there may no longer be an environmental
source, and human strains of GBS may simply be transmitted by
the faecal–oral route. Further exploration of the source of human
GBS carriage may lead to ideas for neonatal disease prevention,
for instance through public health measures.
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